Clinical trial
A Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
NCT03474679 is registered in ClinicalTrials.gov with Janssen Pharmaceutical K.K. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
- Lead sponsor
- Janssen Pharmaceutical K.K.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 1, 2018
- Completion date
- November 29, 2021
- Enrollment
- 19 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.